Evidence map›Paper›PMID 32627611›Full record

ArticleInternational journal of immunopathology and pharmacology

A previously treated severe haemophilia A patient developed high-titre inhibitor after vaccinations.

Zekun Li, Zhenping Chen, Xiaoling Cheng, Xinyi Wu, Gang Li, Yingzi Zhen, Man-Chiu Poon, Runhui Wu

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Zekun LiHemophilia Work Group, Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.ORCID https://orcid.org/0000-0002-1421-4590
Zhenping ChenHemophilia Work Group, Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Xiaoling ChengHemophilia Work Group, Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.ORCID https://orcid.org/0000-0002-0048-2658
Xinyi WuHemophilia Work Group, Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Gang LiHemophilia Work Group, Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Yingzi ZhenHemophilia Work Group, Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Man-Chiu PoonDepartments of Medicine, Pediatrics and Oncology, University of Calgary, Cumming School of Medicine, and Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care program, Foothills Hospital, Alberta Health Services, Calgary, AB, Canada.
Runhui WuHemophilia Work Group, Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Capital Medical University · CNAlberta Health Services · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The factor VIII (FVIII)-neutralizing antibody (inhibitor) seen in 25%-30% of patients with severe haemophilia A (SHA). Vaccination is a non-genetic risk factor of inhibitor development as 'danger signal' which may provide a pro-inflammatory microenvironment to increase FVIII immunogenicity. We reported a previously treated SHA patient postponed the first vaccination to 15-month age received diphtheria-pertussis-tetanus intramuscularly. At 18-month age, the patient received Hepatitis A intramuscularly and Varicella Zoster Virus subcutaneously with 2 weeks interval and FVIII infusion was given <24 h prior for each. Successive bleedings occurred 1 week later with inefficacy of FVIII replacement. High-titre inhibitor was tested at 117 exposure days. This case suggested that continuous vaccinations in close proximity to FVIII could induce inhibitor. The relationship between vaccination and FVIII immunogenicity still needs to be revealed by further study.

Indexed as

Antibodies, NeutralizingChickenpox VaccineCoagulantsDiphtheria-Tetanus-Pertussis VaccineDrug Administration ScheduleFactor VIIIHemophilia AHemorrhageHepatitis A VaccinesHumansInfantMaleSeverity of Illness IndexTreatment OutcomeVaccinationAntibodies, NeutralizingChickenpox VaccineCoagulantsDiphtheria-Tetanus-Pertussis VaccineF8 protein, humanFactor VIIIHepatitis A VaccinesFVIII immunogenicityinhibitorpreviously treated patientsevere haemophilia Avaccination

Identifiers

PMID32627611
PMCPMC7338642
OpenAlexW3039695956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.